Stoke Therapeutics and Biogen Present Long-Term Clinical Data that Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC) | BIIB Stock NewsStockTitan·15 hours agoBIIB+0.83%STOK-1.67%
Biogen And Eisai Announce China Approval For Subcutaneous LEQEMBI To Treat Early Alzheimer's Diseaserttnews·1 day ago, 06:06 AMBIIB+0.83%
Biogen: 4-year Data Support Potential Disease-modifying Effects Of Zorevunersenrttnews·2 days ago, 12:56 PMSTOK-1.67%BIIB+0.83%
Why Veeva Systems (VEEV) Is Up 11.6% After Strong Q2, Higher Guidance, and New AI CRM WinsSimplywall·Aug 30 at 08:21 AMVEEV+1.30%REGN-1.00%
Biogen platforms lupus patient advocate in social media pushFiercepharma·Aug 28 at 01:38 PMBIIB+0.83%
Biogen CEO Viehbacher to speak at Morgan Stanley Global Healthcare ConferencePUBT·Aug 27 at 08:10 PMBIIB+0.83%
4,582 Shares in Biogen Inc. $BIIB Purchased by EFG International AGMarket Beat·Aug 27 at 08:09 AMBIIB+0.83%
Biogen CFO Robin Kramer to join Wells Fargo Healthcare Conference fireside chatPUBT·Aug 26 at 10:59 AMWFC-0.09%BIIB+0.83%
Veeva Vault CRM Selected by Biogen | VEEV Stock NewsStockTitan·Aug 25 at 03:03 AMVEEV+1.30%BIIB+0.83%
Biogen: LEQEMBI IQLIK Autoinjector Available In U.S. For Early Alzheimer'srttnews·Aug 24 at 12:23 PMBIIB+0.83%
Biogen Inc. Stock Outperforms Competitors On Strong Trading DayMarketWatch Automated·Aug 21 at 08:57 PMBIIB+0.83%
